AlphAIAlphAI — Financial news for AI agents
zacks.comOCT 126 min read$TEVA

TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia

Teva Pharmaceutical Industries received FDA approval for Weltruza, a once-monthly injection for schizophrenia. Shares rose 4.7% on Oct. 9. The drug will launch in the U.S. soon, offering an alternative to daily oral treatments. Teva's Uzedy, another schizophrenia treatment, saw sales surge 51% YoY to $140M in H1 2026. Teva also progresses with its branded pipeline, including duvakitug for inflammatory bowel diseases.

Original reporting
zacks.com
Published Oct 12, 2026, 3:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 4:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia — source image
Source · zacks.com
Decision brief

The 30-second read

$TEVABullishMed
01

Why it matters

The FDA nod is a direct, company-specific catalyst that can improve Teva’s product pipeline quality and near-term commercialization expectations, while also highlighting ongoing competitive positioning in LAI antipsychotics.

02

Market read

Traders can reassess Teva’s schizophrenia growth outlook based on a differentiated LAI dosing schedule and imminent US launch plans.

03

What to watch

The article does not quantify expected Weltruza revenue or adoption curve, so the market may overreact to approval versus commercialization execution.

Relevance 7/10Novelty 9/10Timing: launch in the coming weeks after the Oct. 9 FDA approval

Background

Weltruza is an extended-release injectable suspension (olanzapine) positioned as a once-monthly subcutaneous LAI for adult schizophrenia, intended to address adherence challenges versus daily oral therapy.

Company-level read

Ticker impact

$TEVABullishHigh confidence
Context

Teva announced FDA approval of Weltruza, the first and only once-monthly subcutaneous olanzapine LAI for adult schizophrenia, with launch in coming weeks.

Expected impact

Likely upward bias as traders price in commercialization momentum and reduced adherence-related friction for olanzapine LAI.

Evidence & confidence

The article is a primary regulatory approval for Teva’s product, includes launch timing and differentiating dosing attributes, and reports same-day share strength.

Market effects

Sector

Reinforces competitive intensity in long-acting injectable antipsychotics, potentially shifting prescriber preference toward less frequent dosing.

Regional

US-focused catalyst for Teva’s branded schizophrenia portfolio.

Global

Europe review of a related olanzapine LAI application may keep attention on follow-on regulatory timelines.

Counterpoint

What could challenge this read

Approval does not guarantee rapid uptake; payor coverage, real-world tolerability, and competition from Uzedy could limit near-term revenue impact.

Key entities

  • company
    Teva Pharmaceutical Industries Limited

    Issuer of Weltruza and beneficiary of the FDA approval for a once-monthly olanzapine LAI in adult schizophrenia.

  • product
    Weltruza (olanzapine extended-release injectable suspension)

    First and only once-monthly subcutaneous olanzapine LAI formulation approved for adult schizophrenia in the US.

  • clinical_trial
    SOLARIS study

    Phase III study cited as the basis for the FDA approval, reporting improvements in schizophrenia symptoms and functioning.

  • product
    Uzedy

    Teva’s existing once-monthly LAI antipsychotic (approved in the US in 2023) referenced for portfolio context and sales trajectory.

  • partner
    Sanofi

    Partner with Teva on duvakitug development, mentioned as part of Teva’s broader branded pipeline.

Read at source← All news

StoryTeva receives FDA approval for Weltruza, the first once‑monthly subcutaneous olanzapine injection

Also covered by

6 outlets

Related articles

OCT 13
$TEVAHigh

Teva wins FDA approval for schizophrenia injection

Teva Pharmaceuticals received FDA approval for a new injection form of olanzapine, an antipsychotic drug for schizophrenia. The company claims this could improve patient adherence compared to daily oral treatment, potentially reducing relapse risks. Olanzapine is the most widely prescribed atypical antipsychotic.

lifesciencesweden.se1 min
OCT 13
$TEVAHigh

USFDA Approves Teva's Once-Monthly Schizophrenia Injection Weltruza

Teva, in partnership with Medincell, received USFDA approval for Weltruza, a once-monthly schizophrenia injection. Teva expects to launch the drug in the US soon. Medincell's technology enables extended-release medication. Analysts note potential for improved treatment adherence. Medincell may receive up to $112 million in milestone payments and royalties. Teva's shares rose 2% in Tel Aviv; Medincell's shares gained 16.9% in Paris.

medicaldialogues.in2 min
OCT 12
$TEVAHigh

FDA Approves Once-Monthly Olanzapine Injection for Adults with Schizophrenia

The FDA approved Teva Pharmaceuticals' once-monthly olanzapine injection (Weltruza) for adults with schizophrenia. The subcutaneous injection uses novel technology for steady release, eliminating post-injection monitoring. The approval was based on the Phase 3 SOLARIS trial, showing significant symptom reduction and a safety profile consistent with oral olanzapine.

drugtopics.com3 min
OCT 12
$TEVAHigh

FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia

Teva Pharmaceuticals' Weltruza, a once-monthly subcutaneous olanzapine injection, received FDA approval for treating schizophrenia. The treatment requires no loading doses or postinjection monitoring. It will be available in doses of 318 mg, 425 mg, and 531 mg, corresponding to daily oral olanzapine doses. The approval was based on the SOLARIS trial, which showed significant improvements in symptoms compared to placebo.

pharmacytimes.com3 min
OCT 12
$TEVAMed

Teva wins FDA approval for once-monthly olanzapine injection

Teva Pharmaceuticals received FDA approval for WELTRUZA, a once-monthly olanzapine injection for schizophrenia. Developed with Medincell's SteadyTeq technology, it requires no loading doses or post-injection monitoring. Teva plans a US launch in three strengths. The approval follows positive Phase III trial results, showing symptom improvements and a safety profile consistent with oral olanzapine. Medincell may earn royalties and milestone payments.

manufacturingchemist.com5 min
OCT 12
$TEVAHigh

Morning Rounds: October 5-12

FDA approved Teva's Weltruza, a once-monthly olanzapine injection for schizophrenia, based on phase 3 trial results. Motivista's CT-155, a digital therapeutic, received clearance for negative schizophrenia symptoms. Neurosterix's NTX-253 completed phase 1 and will enter phase 2. Newron's evenamide faces a US trial hold due to 4 deaths in studies.

psychiatrictimes.com2 min